RXRA and prostate cancer: Although AT treatment did not affect the mRNA levels of the androgen-responsive genes assessed, AT produced a 20% reduction in RXRα mRNA levels (Fig 5D), providing further support for differential effects of AT and TQ on prostate cancer cells.